Nuvectis Pharma, Inc. (NASDAQ:NVCT – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the five analysts that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $36.25.
Several research firms have recently weighed in on NVCT. UBS Group set a $33.00 price objective on shares of Nuvectis Pharma in a report on Monday, July 6th. Cantor Fitzgerald began coverage on Nuvectis Pharma in a report on Monday, August 24th. They issued an “overweight” rating on the stock. Loop Capital set a $40.00 price target on Nuvectis Pharma in a report on Tuesday. Wall Street Zen upgraded Nuvectis Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings upgraded Nuvectis Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th.
Read Our Latest Research Report on NVCT
Nuvectis Pharma Stock Up 1.9%
Nuvectis Pharma (NASDAQ:NVCT – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.04). On average, equities research analysts anticipate that Nuvectis Pharma will post -1.01 EPS for the current year.
Insider Transactions at Nuvectis Pharma
In related news, major shareholder Marlio Charles Mosseri acquired 50,000 shares of the stock in a transaction on Tuesday, June 30th. The stock was purchased at an average price of $18.32 per share, for a total transaction of $916,000.00. Following the transaction, the insider owned 3,186,576 shares of the company’s stock, valued at $58,378,072.32. The trade was a 1.59% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ron Bentsur acquired 12,500 shares of the stock in a transaction on Tuesday, June 30th. The stock was bought at an average price of $20.00 per share, with a total value of $250,000.00. Following the transaction, the chief executive officer directly owned 3,688,424 shares in the company, valued at approximately $73,768,480. This represents a 0.34% increase in their position. The SEC filing for this purchase provides additional information. Insiders own 28.55% of the company’s stock.
Institutional Trading of Nuvectis Pharma
Several hedge funds have recently modified their holdings of NVCT. BlackRock Inc. bought a new position in Nuvectis Pharma in the 2nd quarter worth approximately $18,414,000. Vanguard Group Inc. boosted its position in Nuvectis Pharma by 4.8% in the 3rd quarter. Vanguard Group Inc. now owns 698,708 shares of the company’s stock valued at $4,206,000 after buying an additional 31,903 shares during the last quarter. Occam Crest Management LP increased its stake in shares of Nuvectis Pharma by 31.0% in the 4th quarter. Occam Crest Management LP now owns 380,000 shares of the company’s stock valued at $2,869,000 after buying an additional 90,000 shares during the period. Geode Capital Management LLC raised its position in shares of Nuvectis Pharma by 11.8% during the fourth quarter. Geode Capital Management LLC now owns 364,024 shares of the company’s stock worth $2,749,000 after acquiring an additional 38,291 shares during the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Nuvectis Pharma during the second quarter worth $5,057,000. 96.77% of the stock is owned by institutional investors.
Nuvectis Pharma Company Profile
Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.
The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.
Featured Stories
- Five stocks we like better than Nuvectis Pharma
- Accelerant’s Take-Private Deal Raises a Bigger Question for Insurance Stocks
- 3 CEOs Are Buying Millions of Dollars of Their Beaten-Down Stocks
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
